Navigating Innovation and Affordability in a Changing Healthcare Landscape: Will this impact your start up?

The Inflation Reduction Act (IRA), often called “One Big Beautiful Bill,” could significantly impact the future of medical device research and development. By prioritizing healthcare affordability and innovation, the IRA encourages investment in advanced technologies and cost-effective solutions. For medical device companies, this means increased pressure to innovate efficiently while managing pricing and reimbursement challenges. C-Level Strategy helps clients navigate these changes by aligning R&D and product development efforts with evolving policy requirements, ensuring your innovations stay competitive and compliant in a shifting healthcare landscape.